|Bid||65.50 x 800|
|Ask||66.73 x 900|
|Day's Range||65.10 - 73.68|
|52 Week Range||8.69 - 84.49|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 04, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||53.75|
Chuck Norris has... some kind of limitation, I'm sure. Thirty-five states have legalized medical cannabis. Cresco Labs (OTC: CRLBF) ranks as one of the largest multistate cannabis operators and is profiting tremendously from the cannabis boom.
DermTech (NASDAQ: DMTK) is one of several companies that have gone public via a merger with a special purpose acquisition company (SPAC). In this Motley Fool Live video recorded on Feb. 17, 2021, Fool.com contributors Keith Speights and Brian Orelli talk about why DermTech is a good stock to buy right now. Aaron asks thoughts on DermTech; the ticker there is DMTK.
DermTech, Inc. (NASDAQ: DMTK) ("DermTech"), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that four of its abstracts were selected by the Society for Investigative Dermatology ("SID") for presentation at the SID Virtual Meeting, taking place May 3-8, 2021. The SID is committed to the advancement of skin health and disease through education, advocacy and scholarly exchange of scientific information. In addition to virtual sessions, the abstracts will be published in a forthcoming supplemental issue of the Journal of Investigative Dermatology.